Aptamers Market

An aptamer binds like an antibody but is made in a tube rather than an animal, which changes the cost, the consistency and the regulatory conversation all at once. Douglas Insights values the aptamers market at USD 2.15 billion in 2025 and expects USD 8.37 billion by 2035, compounding at 14.57%. The estimate is built from the bottom up: roughly 4,150 active aptamer programs and deployments worldwide, therapeutic pipelines, diagnostic and analytical assays, proteomics services and research reagent lines, at an average annual value of USD 518,000 per program, triangulated against platform-company disclosures, pipeline databases and reagent catalogue economics. Growth splits into two engines: program and assay activity expands 10.8% a year, and value per program rises 3.4% a year as work migrates from reagent-scale research toward clinical and service-scale deployments.

The verdict

Aptamers spent two decades as the nucleic-acid technology that always promised and rarely delivered, and that era has ended. The 2023 approval of avacincaptad pegol, only the second aptamer drug ever, revalidated the modality with regulators, licensors and investors at once. Diagnostics and analytical uses earn the most today because they never needed the therapeutic bet to pay, proteomics services are the scale engine, and therapeutics are the option value now being repriced deal by deal. Antibodies remain the incumbent for almost everything aptamers do, so aptamer growth comes from the niches where they are structurally better: thermal stability, batch consistency, small-target binding and rapid re-selection.

What are aptamers?

Aptamers are short single-stranded oligonucleotides, DNA aptamers or RNA aptamers, selected to fold into shapes that bind targets with antibody-like affinity and produced chemically rather than biologically. Modified chemistries including conjugates, such as PEGylated or nuclease-resistant backbones, extend their life in the body. Aptamers serve as therapeutic agents, recognition elements for diagnostics developers, analytical affinity reagents and the binding layer of large proteomics platforms. The aptamers market covers therapeutics revenue, diagnostics and analytical products, selection and development services, and research reagents, at vendor value. The category sits within our life science instruments coverage.

Why did the second aptamer approval change the mood?

In August 2023 the US Food and Drug Administration approved Astellas’s avacincaptad pegol (Izervay) for geographic atrophy, the first new aptamer drug since pegaptanib was approved in December 2004, as listed in the FDA’s 2023 novel drug approvals. That 19-year gap had defined aptamer economics: the modality carried a discount in every licensing talk, and platform companies lived on services and reagents. The approval showed that modern aptamer chemistry survives regulatory review end to end, put a commercial royalty stream behind the modality, and did so in the eye, where aptamer pharmacokinetics help rather than hurt. The model treats it as a demand event: program formation, partnering and selection bookings all stepped up afterwards.

What drives demand for aptamers?

Aptamer-based proteomics at scale is the first driver, and the fastest: proteomics services hold 13% of 2025 revenue, USD 279 million, and grow faster than any other segment. Platforms such as SomaScan measure about 7,000 to 11,000 proteins per sample on aptamer arrays, so every biobank study, pharma discovery deal and clinical-validation program adds recurring assay volume, and the model links the segment to announced cohort commitments. A single population cohort can run tens of thousands of samples, and each sample is billed per assay, so one signed cohort shows up as years of aptamer service revenue rather than a one-off sale.

Computational selection is the second driver. Machine-learning-guided libraries and in-silico maturation compress aptamer selection from months toward weeks, cutting cost where the field was expensive and widening the funnel of viable targets. The model carries this as program growth of 10.8% a year, taking active programs from about 4,150 in 2025 to about 11,600 in 2035. Cheaper selection matters most for diagnostics developers and academic groups, who fund aptamer work from small budgets and would not start a program that took a year to return a binder.

The diagnostics fit is the third driver. Aptamers tolerate heat, dry storage and chemical manufacture in ways antibodies do not, which suits point-of-care tests, biosensors and continuous-monitoring concepts, a design space also covered in our Continuous Glucose Monitoring Sensor Manufacturing Market report. Diagnostics and analytical products already lead the aptamers market with 34% of 2025 revenue, and the case is strongest where cold chains fail: a test that needs no refrigeration reaches clinics an antibody test cannot.

The post-approval therapeutic wake is the fourth driver. Ophthalmology and complement biology lead a rebuilt aptamer pipeline, therapeutics and pipeline services hold 24% of revenue, and each partnering deal since August 2023 has lifted value per program, which rises 3.4% a year in the base case. A third approval inside the forecast window is the single event that would move the aptamers market fastest, and the momentum scenario prices exactly that.

What holds back the aptamers market?

Three restraints are modelled, and together they pull the 2035 figure down to about USD 5.60 billion in the setback case. Antibody incumbency leads: decades of validated antibody infrastructure and manufacturing scale mean aptamers win only where they are structurally better. Nuclease fragility and delivery are second: unmodified aptamers degrade in serum within minutes and clear through the kidney, so every therapeutic needs chemistry and conjugation that adds cost and risk. Concentration risk is third: much near-term aptamer revenue rests on a few proteomics platforms and one young therapeutic franchise, so a single setback moves the market visibly. The setback scenario applies exactly that shock, trimming program growth from 10.8% to 7.8% a year.

Which aptamer application carries the value?

Diagnostics and analytical applications lead with 34% of 2025 revenue, USD 730.5 million, where chemical manufacture undercuts antibody economics. Research reagents and tools hold 29%, USD 623 million, the stable base of catalogue aptamers and custom selections. Therapeutics and pipeline services, including royalty flows, take 24%, USD 515.7 million, the fastest-repricing segment since the 2023 approval. Aptamer-based proteomics services contribute 13%, USD 279 million, and grow fastest, at about 20.5% a year, on cohort-scale deployments.

Which regions fund aptamer work?

North America leads the aptamers market with 44% of 2025 revenue, USD 945 million, on platform-company concentration, biopharma partnering depth and cohort-study funding, compounding at 14.2% a year. Europe follows at 26%, USD 559 million, at 13.8%, with strong academic selection science and biobank proteomics. Asia Pacific grows fastest at 16.0% as Chinese and Japanese groups scale both selection services and diagnostics manufacturing. Latin America contributes USD 64.5 million, the Middle East USD 43.0 million on research-hub investment, and Africa USD 21.4 million. Six regional models sum to the global figure.

Who builds the aptamer platforms?

Five companies anchor the aptamers market. Standard BioTools leads proteomics through the SomaLogic platform, the largest aptamer deployment in routine operation. Astellas owns the therapeutic validation event through avacincaptad pegol. Aptamer Group leads dedicated selection services across therapeutics and diagnostics, Base Pair Biotechnologies supplies custom aptamers to assay developers, and NeoVentures Biotechnology holds long-standing positions in food-safety and analytical aptamers. Around them sit oligonucleotide manufacturers and a venture-funded therapeutic cohort rebuilt since 2023. The competitive chapter profiles each player’s platform economics and partnering pipeline.

How are aptamer programs priced?

An active aptamer program is worth USD 518,000 a year on average in 2025, across a wide ladder: catalogue reagent lines in the tens of thousands of dollars, custom selection programs from the low hundreds of thousands, cohort-scale proteomics engagements in the millions, and clinical therapeutic programs at the top before royalties. The 3.4% annual rise in value per program is mix, as work shifts toward clinical and service scale. The pricing chapter publishes selection-service rate cards, proteomics per-sample economics and reagent pricing against antibody equivalents.

How do the aptamer scenarios diverge by 2035?

The aptamers base case carries 10.8% program growth and 3.4% value mix for a 14.57% revenue CAGR and USD 8.37 billion in 2035. The setback scenario, applying a major platform or clinical disappointment mid-window, trims the legs to 7.8% and 2.2%, landing near USD 5.60 billion. The modality-momentum scenario, with a third approval and proteomics cohorts compounding, lifts them to 12.6% and 4.2%, carrying the market past USD 10.5 billion. Each 1-point change in program growth moves the 2035 figure by roughly USD 700 million. Published forecasts span roughly 15% to 20% on looser definitions; ours sits lower on a vendor-revenue boundary.

Which regulatory pathways apply to aptamers?

Aptamers cross three regulatory worlds. Aptamer therapeutics follow standard drug pathways with oligonucleotide impurity control and conjugate characterisation, and the 2023 avacincaptad file is now the reference dossier. Aptamer diagnostics carry device regulation within IVD frameworks, whose European transition raised evidence requirements for every assay class. Research and proteomics services sit lightest, but clinical-decision use pulls laboratory-developed-test rules into scope. The regulatory chapter maps each pathway by market and tracks the foundational selection patents whose expiry opened the field.

Douglas Exclusive: the aptamer program pipeline tracker

The aptamers market hangs on a countable set of programs, so this report maintains the count: the therapeutic pipeline by phase, indication and chemistry, the proteomics cohort book, diagnostic programs approaching market, and the licensing-deal log with disclosed economics. Licence holders receive it as a maintained tab in the Excel model.

How is an aptamer made, and where does it beat antibodies?

An aptamer is selected rather than designed: a starting library of around a thousand trillion random sequences is exposed to the target, binders are captured and amplified, and the cycle repeats 8 to 15 times under harsher conditions until only tight binders remain. The work takes weeks to months against many months for a monoclonal antibody, and needs no animals. Because aptamers are made chemically, batch variation is minimal, they are stable at room temperature and can be regenerated on sensor surfaces, which suits biosensors, lateral flow tests and affinity ligands. Binding is typically characterised label-free, the instrument base sized in our Surface Plasmon Resonance Market report.

Why have aptamer therapeutics been so difficult?

Only 2 aptamer drugs reached approval in 19 years, and the reasons are pharmacological. Unmodified nucleic acids are cleared from the blood in minutes, so a therapeutic aptamer needs chemical modification and often a polyethylene glycol tail, which adds cost and its own safety questions. Delivery inside cells remains hard, so most clinical work targets extracellular proteins or local injection into the eye. Pegaptanib lost ground commercially once anti-VEGF antibodies proved more effective, and the model keeps aptamer therapeutic revenue modest, treating clinical readouts as the main upside risk.

Methodology and receipts

The aptamers model is built bottom-up from about 4,150 active programs in 2025, split across 4 applications, 3 chemistry types, 6 regions and 4 end-user groups (biopharma, diagnostics developers, academic and government research, and population-cohort programs), each valued at evidenced per-program economics averaging USD 518,000, with growth decomposed as programs times value per program. The vendor-revenue boundary excludes downstream drug sales beyond royalty flows. Every figure carries a numbered source and a confidence grade in the fact sheet above. The full method follows the published Douglas Insights methodology. The next scheduled review of this study is September 2027.

Sources

1. US Food and Drug Administration Novel Drug Approvals for 2023 (2023)